Kazia Therapeutics Ltd ADR - Asset Resilience Ratio
Kazia Therapeutics Ltd ADR (KZIA) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check KZIA PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2019)
This chart shows how Kazia Therapeutics Ltd ADR's Asset Resilience Ratio has changed over time. See Kazia Therapeutics Ltd ADR (KZIA) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Kazia Therapeutics Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see KZIA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Kazia Therapeutics Ltd ADR maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Kazia Therapeutics Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Kazia Therapeutics Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Kazia Therapeutics Ltd ADR (2006–2019)
The table below shows the annual Asset Resilience Ratio data for Kazia Therapeutics Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-06-30 | 0.00% | $0.00 | $21.18 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $28.18 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $35.91 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $35.52 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $46.14 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $4.66 Million | -- |
| 2012-06-30 | 2.85% | $256.00K | $8.98 Million | +0.74pp |
| 2011-06-30 | 2.11% | $268.00K | $12.73 Million | -2.29pp |
| 2010-06-30 | 4.40% | $848.00K | $19.29 Million | +2.27pp |
| 2009-06-30 | 2.13% | $806.00K | $37.84 Million | -12.56pp |
| 2008-06-30 | 14.69% | $6.37 Million | $43.38 Million | -3.16pp |
| 2006-06-30 | 17.85% | $9.13 Million | $51.11 Million | -- |
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase I… Read more